Product Description
IMM-101 has been shown to be an excellent activator of dendritic cells (DCs) (and several other innate immune cells, such as macrophages and natural killer cells). This activation is thought to be predominantly caused by the binding of certain of IMM-101Õs containingÊMycobacterium obuenseÊbacterial cell wall components (such bacterial compounds are called in general Microbial Associated Molecular Pattern molecules (MAMPs)) to a specific group of receptors that are expressed on the surface or inside phagocytotic compartments of DCs. (Sourced from: https://www.immodulon.com/more-about-imm-101-moa/)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Immodulon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, United Kingdom
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: COVID-19
Phase 2: Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| COV-IMMUNO | P3 |
Active, not recruiting |
COVID-19 |
2024-05-07 |
|
| IMM-101-015 | P2 |
Completed |
Melanoma |
2021-12-02 |